OvaScience (OVAS) and Its Rivals Financial Comparison
OvaScience (NASDAQ: OVAS) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare OvaScience to similar companies based on the strength of its risk, profitability, institutional ownership, valuation, analyst recommendations, earnings and dividends.
Risk & Volatility
OvaScience has a beta of 3.73, meaning that its stock price is 273% more volatile than the S&P 500. Comparatively, OvaScience’s rivals have a beta of 1.47, meaning that their average stock price is 47% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for OvaScience and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OvaScience currently has a consensus target price of $8.00, suggesting a potential upside of 620.72%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.31%. Given OvaScience’s higher probable upside, equities analysts clearly believe OvaScience is more favorable than its rivals.
Earnings & Valuation
This table compares OvaScience and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|OvaScience Competitors||$207.03 million||-$40.51 million||-65.75|
OvaScience’s rivals have higher revenue and earnings than OvaScience. OvaScience is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares OvaScience and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
55.1% of OvaScience shares are held by institutional investors. Comparatively, 49.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 9.5% of OvaScience shares are held by company insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
OvaScience rivals beat OvaScience on 9 of the 13 factors compared.
OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with Analyst Ratings Network's FREE daily email newsletter.